Publications by authors named "Denise N Morris"
Physiologically based pharmacokinetic (PBPK) modeling requires an understanding of chemical, physiologic, and pharmacokinetic principles. Active learning with PBPK modeling software (GastroPlus) may be useful to teach these scientific principles while also teaching software operation. To examine this issue, a graduate-level course was designed using learning objectives in science, software use, and PBPK model application.
View Article and Find Full Text PDFIntroduction: Augmentation therapy with plasma-derived α-proteinase inhibitor (A1PI) products is currently the only approved disease-specific therapy for α-antitrypsin deficiency (AATD), a genetic disorder associated with decreased levels of A1PI. Systemic trough levels of A1PI in plasma or serum are widely accepted as a biochemical efficacy endpoint in clinical trials for A1PI products.
Methods: Retrospective analyses utilizing data from three clinical studies in patients with AATD were conducted to evaluate the pharmacokinetic(s) (PK) and biochemical efficacy comparability of Aralast NP and two other A1PI augmentation therapies, Aralast and Prolastin.
There is a pressing need to improve the efficiency of drug development, and nowhere is that need more clear than in the case of neglected diseases like malaria. The peculiarities of pyrimidine metabolism in Plasmodium species make inhibition of dihydroorotate dehydrogenase (DHODH) an attractive target for antimalarial drug design. By applying a pair of complementary quantitative structure-activity relationships derived for inhibition of a truncated, soluble form of the enzyme from Plasmodium falciparum (s-PfDHODH) to data from a large-scale phenotypic screen against cultured parasites, we were able to identify a class of antimalarial leads that inhibit the enzyme and abolish parasite growth in blood culture.
View Article and Find Full Text PDFArticle Synopsis
- Fremanezumab is a monoclonal antibody designed to prevent migraines in adults, with its pharmacokinetics (how the drug moves through the body) analyzed in various patient groups.
- * The study employed nonlinear mixed effects modeling to evaluate data from 7 clinical trials focused on different dosing methods, ensuring comprehensive assessment of how factors like body weight affect drug clearance.
- * The findings established a reliable model for fremanezumab's pharmacokinetics, indicating that factors like weight impact drug distribution, while other elements such as age and sex showed no significant influence, aiding future research on drug efficacy and safety.